AIM ImmunoTech
Tracked across 2 events · 16 articles · First seen Feb 05, 2026 · Last active Mar 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
AIM ImmunoTech Inc. announced milestones for its Phase 2 clinical study of AIM ImmunoTech===Rintatolimod combined with AstraZeneca===Durvalumab for metastatic pancreatic cancer. The company is prioritizing AIM ImmunoTech===Rintatolimod's approval for pancreatic cancer, which could lead to significant financial potential for its stockholders through potential mergers and acquisitions.
Feb 05, 2026 · 9 articles
Business
AIM ImmunoTech Inc. conducted a rights offering to raise approximately $1.8 million. This offering allows existing shareholders to purchase new units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants, aiming to secure additional capital for its research and development efforts, particularly for Ampligen.
Feb 11, 2026 · 7 articles
Erasmus MC
collaborator
↔
AIM ImmunoTech
AIM ImmunoTech and Erasmus MC are collaborating on the DURIPANC clinical study.
AIM ImmunoTech===Rintatolimod
lead product
↔
AIM ImmunoTech
AIM ImmunoTech===Rintatolimod is the lead drug product being developed by AIM Im
NEWSDESK
Track AIM ImmunoTech live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard